Vyvgart Hytrulo’s under-the-skin administration means it can be given in 30 to 90 seconds, compared with one hour for the intravenous product. It will be priced at parity to Vyvgart, which has a net price of $225,000 annually.
Formulary Watch
Latest News
All News
Advertisement
Jardiance and Synjardy are the first SGLT2 inhibitors approved for children with type 2 diabetes.
Employers and plans need to prioritize clinical efficacy over drug price, look for price reductions — and not rebates — on biosimilars, and advocate for a public option to cover gene therapies. These are just a few of ideas that consultant Alex Jung put forward at a meeting of the Midwest Business Group on Health.
Imetelstat targets telomerase to inhibit uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies.
Lodoco targets the inflammation that is an underlying cause of atherosclerotic cardiovascular disease. It will be available in the second half of 2023.
The FDA is requesting additional data and analysis for olorofim. F2G plans to resubmit revised NDA with complete data set from phase 2 study.
About a quarter of those surveyed said their insurance didn’t cover a needed prescription drug or charged a very high copay.
Columvi will cost about $350,000 for a fixed duration therapy with 12 treatments over eight and a half months.
The supply interruption is the result of a combination of factors, including significant increases in demand, an increase in syphilis infection rates, as well as competitive shortages.
If passed, PBMs would not be able to charge fees that are connected to the price of a drug, discounts, or rebates.
Advertisement
Ziprasidone is used to treat patients with schizophrenia and bipolar disorder. Taking dronabinol instead may lead to worsening of mental illness symptoms.
Ozempic, Wegovy and other GLP-1 drugs present a challenge to payers in terms of costs and outcomes, finds PSG’s new Drug Benefit Design Report.
SmithRx will offer Yusimry through Mark Cuban’s online pharmacy for $569.27, and members will be able to apply their insurance benefits.
Linzess is first FDA-approved prescription therapy for functional constipation in children 6 to 17 years of age.
If approved, nirsevimab would be the first immunization specifically to protect infants through their first RSV season. The Prescription Drug User Fee Act date is in the third quarter of 2023.
More than 90% of cancer centers have experienced shortages of critical drugs. Erin R. Fox, Pharm.D., University of Utah Health, talks about why these shortages are happening and efforts that are being made to address them.
Exagamglogene autotemcel is being evaluated for patients with sickle cell disease and beta thalassemia, in which a patient’s own hematopoietic stem cells are edited to produce high levels of fetal hemoglobin in red blood cells.
Vevye (previously CyclASol) is a water-free, preservative-free solution, which allows for improved bioavailability and better efficacy on the target tissue.
Renee Rayburg talks about how paying for specialty drugs continues to be a top concern for both health plans and employers.
The FDA has received adverse event reports after patients have used compounded semaglutide that contains salt formulations, which are different active ingredients than that used in the agency-approved drugs for diabetes and weight loss.
The median annual cost for new oncology medicines launched in 2022 was $260,000, up from $63,534 10 years ago, an IQVIA report finds.
The FDA has assigned an action date of Sept. 23, 2023. If approved, this would be the first frontline treatment advancement in decades for patients with advanced or recurrent endometrial cancer.
In an analysis, researchers determined that Inpefa is cost-effective at commonly accepted willingness-to-pay thresholds in treating patients with heart failure who have diabetes.
Prevymis was approved to prevent CMV infection in adults after an allogeneic hematopoietic stem cell transplant in 2017.
The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.
The drugs must have full “traditional” FDA approval and patients need to be enrolled in a registry that collects post-approval data efficacy and safety when the drugs are used in clinical practice.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
2
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
3
Optimal Physical Activity for Preventing Digestive System Cancers
4
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
5
